The 36-month beta value for AUTL is at 2.01. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUTL is 236.67M, and currently, shorts hold a 2.66% of that float. The average trading volume for AUTL on December 18, 2024 was 1.68M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AUTL) stock’s latest price update
Autolus Therapeutics plc ADR (NASDAQ: AUTL) has seen a decline in its stock price by -3.39 in relation to its previous close of 2.49. However, the company has experienced a -17.05% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-09 that LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus.
AUTL’s Market Performance
Autolus Therapeutics plc ADR (AUTL) has experienced a -17.05% fall in stock performance for the past week, with a -19.55% drop in the past month, and a -37.52% drop in the past quarter. The volatility ratio for the week is 7.72%, and the volatility levels for the past 30 days are at 7.21% for AUTL. The simple moving average for the past 20 days is -17.04% for AUTL’s stock, with a -41.80% simple moving average for the past 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the current year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at -31.26% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.71% of loss for the given period.
Volatility was left at 7.21%, however, over the last 30 days, the volatility rate increased by 7.72%, as shares sank -18.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.76% lower at present.
During the last 5 trading sessions, AUTL fell by -17.07%, which changed the moving average for the period of 200-days by -57.81% in comparison to the 20-day moving average, which settled at $2.90. In addition, Autolus Therapeutics plc ADR saw -62.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -17.4 for the present operating margin
- 0.52 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -22.77. The total capital return value is set at -0.27. Equity return is now at value -82.20, with -43.81 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -54.14. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -2.94.
Currently, EBITDA for the company is -156.77 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.88. The receivables turnover for the company is 11.95for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.64.
Conclusion
In conclusion, Autolus Therapeutics plc ADR (AUTL) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
